2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1665

Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
Abstract Number: 1666

The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Abstract Number: 1667

Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
Abstract Number: 1668

Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus
Abstract Number: 1669

iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites
Abstract Number: 1670

Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes
Abstract Number: 1671

Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 1672

Poor Sleep Quality Predicts Worsening SLE Disease Activity
Abstract Number: 1673

Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
Abstract Number: 1674

Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
Abstract Number: 1675

Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Abstract Number: 1676

Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Abstract Number: 1677

Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 1678

How Consistently Do Publications Define SLE? a Systematic Review
Abstract Number: 1679

Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].